Eli Lilly launches Foundayo, second daily weight loss pill in the US

Eli Lilly received approval from the American regulatory agency to market Foundayo, an oral medicine for the treatment of obesity and overweight. Authorization took place on April 1, 2026 and marks the arrival of the second daily glp-1 tablet on the Estados Unidos market. The product is positioned as a practical alternative to weekly injections and the first oral tablet released in December 2025.

Características and how to use the new medicine

Foundayo is a small molecule glp-1 receptor agonist taken once daily. Diferente from other medications in the same class, can be taken at any time, regardless of meals or dietary restrictions. Essa’s flexibility facilitates patient compliance compared to options that require fasting or specific intake times.

The medicine works by mimicking a natural hormone that regulates appetite and promotes a feeling of satiety. Estudos clinicians demonstrated a mean reduction of 12% in body weight at the highest dose over 72 weeks. Pacientes also showed improvement in metabolic parameters, including glycemic control.

Resultados from clinical trials and accelerated approval

• Redução averaged 12% of body weight at the highest dose over 72 weeks of treatment.
• Aprovação granted in less than four months through FDA priority program.
• Indicado for adults with obesity or overweight associated with at least one weight-related condition.

The FDA evaluated safety and efficacy data before granting accelerated approval. The most common side effects include gastrointestinal symptoms, a pattern observed in medications in the same class. The agency prioritized new options for controlling obesity, a condition that affects millions of adults in the Estados Unidos.

Estratégia of distribution and access to medicine

Eli Lilly plans to begin distributing Foundayo in the coming weeks. The company offers a discount program that can reduce the monthly cost to approximately $25 for eligible patients with health insurance. Essa strategy seeks to expand access to treatment in a market that already records hundreds of thousands of prescriptions for the first oral tablet available.

Leia Tambem

PlayStation Plus releases free Woodle Tree Adventures Deluxe to subscribers for redemption until May 28, 2026

FIFA defines the use of exclusive stamps on the shirts of players awarded during the World Cup

Toyota launches Hilux GR pickup truck in Japan for US$31,200 and confirms mild hybrid version in 2027

The medication should be used in conjunction with a low-calorie diet and increased physical activity for sustainable results. Profissionais Health hopes the increased convenience will encourage greater adherence to weight loss protocols. The absence of dietary restrictions represents a practical advantage that can improve treatment persistence.

Competição among laboratories in the obesity market

The approval of Foundayo reinforces the competition between Eli Lilly and Novo Nordisk in the weight loss treatments segment. The first glp-1 oral tablet, Wegovy version of Novo Nordisk, received approval in December 2025 and has already accumulated more than 600 thousand prescriptions for Estados Unidos. Ambas companies are leading the development of glp-1 agonists, initially with injectables and now with oral formulations.

Analistas follows how the availability of oral options can attract new patients who avoid injections. The global obesity drug market continues to expand rapidly. Competition between laboratories should drive additional innovations in the coming years, diversifying therapeutic strategies in the field of weight management.